BOULDER, Colo. – November 04, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) reported third-quarter 2026 net income of $1,166.2 million, or $9.65 per diluted share, driven by a $1.348 billion gain on the sale of its sevasemten program and muscular dystrophy business to Servier. In the same period of 2025, the company posted a net loss of $40.7 million, or $0.39 per share.
Servier sale delivers $1.396 billion in upfront cash
The transaction closed in July 2026. Edgewise received $1.396 billion in upfront cash at closing. The reported gain includes consideration recognized at closing, among it amounts tied to the general indemnification arrangement. It is stated net of the carrying value of transferred assets, transaction costs and consideration allocated to transition services. Income tax expense associated with the transaction partly offset the gain in net income.
Cash, cash equivalents and marketable securities stood at approximately $1,743.9 million as of September 30, 2026. Edgewise's risk disclosures flag the possibility that it may not receive amounts held in escrow or milestone payments related to the transaction.
R&D spending falls to $31.6 million as G&A rises 55%
R&D expenses were $31.6 million, down from $37.5 million a year earlier. Lower sevasemten costs following the Servier sale drove the decline. Higher spending on EDG-7500, discovery and preclinical programs, and personnel partially offset it.
G&A expenses rose to $14.6 million from $9.4 million. Edgewise attributed the increase to higher personnel costs, including stock-based compensation, as it expanded capabilities for clinical development, along with higher professional fees and other administrative costs.
EDG-7500 Phase 3 in HCM on track to start by end-2026
Edgewise expects to initiate a Phase 3 trial of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) by the end of 2026. The oral, first-in-class cardiac sarcomere modulator acts on the regulatory light chain to slow early contraction velocity and improve impaired cardiac relaxation.
In August 2026, the company presented positive top-line results from the 12-week, open-label Phase 2 Part D CIRRUS-HCM trial as a late-breaking presentation at the European Society of Cardiology Congress. CIRRUS-HCM was designed to inform the Phase 3 program. Edgewise also published the preclinical pharmacologic profile of EDG-7500 in JCI Insight. The data support improved cardiac relaxation while preserving overall systolic performance, and early clinical observations in symptomatic HCM patients have been consistent with them.
First patient dosed in Phase 2 EQUINOX-HFpEF trial of EDG-15400
Edgewise dosed the first patient in the Phase 2 EQUINOX-HFpEF trial of EDG-15400, an oral, selective cardiac sarcomere modulator. The study enrolls adults with symptomatic heart failure with preserved ejection fraction (HFpEF) and a left ventricular ejection fraction of at least 50% (ClinicalTrials.gov: NCT07795814). EDG-15400 has shown improved diastolic function in preclinical models and targets impaired cardiac relaxation, which the company describes as a hallmark of HFpEF.
CEO Kevin Koch said the quarter reflected continued execution across both cardiovascular programs.